Search Results - Orwitz, Nina

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity

    T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity by Ikegawa, Shuntaro, Sperling, Adam S., Ansuinelli, Michela, Nikiforow, Sarah, Quinn, David, Bu, Dexiu, Mataraza, Jennifer, Pearson, David, Rispoli, Lawrence, Credi, Marc A, Orwitz, Nina, Arihara, Yohei, Prabhala, Rao, Potluri, Lakshmi Bhavani, Reynolds, Carol, Vita, Serena De, Munshi, Nikhil C, Ritz, Jerome

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform

    Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform by Ikegawa, Shuntaro, Sperling, Adam S., Nikiforow, Sarah, Ghazi, Andrew, Christidis, Anthony, Quinn, David, Bu, Dexiu, Mataraza, Jennifer, Pearson, David, Charles, Allison, Credi, Marc, Orwitz, Nina, Strange, Madisyn, Tamada, Rakuyo, Panaro, Kevin M., Gervais, Casey, Ansuinelli, Michela, Arihara, Yohei, Prabhala, Rao, Reynolds, Carol G., Gentleman, Robert, Vita, Serena De, Munshi, Nikhil C., Ritz, Jerome

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    OA-06 Robust in vivo expansion and long-term persistence of anti-BCMA CAR T cells, PHE885, manufactured in <2 days on the T-Charge platform

    OA-06 Robust in vivo expansion and long-term persistence of anti-BCMA CAR T cells, PHE885, manufactured in <2 days on the T-Charge platform by Ikegawa, Shuntaro, Prabhala, Rao, Sperling, Adam, Nikiforow, Sarah, Quinn, David, Bu, Dexiu, Mataraza, Jennifer, Pearson, David, Rispoli, Lawrence, Credi, Marc, Orwitz, Nina, Potluri, Laksmi, Arihara, Yohei, Reynolds, Carol, Ansuinelli, Michela, Nguyen, Tuyet, Vita, Serena, Munshi, Nikhil, Ritz, Jerome

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib

    Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib by Rogers, Kerry Anne, Yan, Pearlly, Flinn, Ian W., Stephens, Deborah M., Kipps, Thomas J., Larson, Sarah M., Martz, Laura, Chen, Xi, Wang, Huabao, Hopping, Ethan, Bundschuh, Ralf, Acosta, Alexandra, Baldoni, Daniela, Chaudhury, Anwesha, Whalen, Jeanne, Hassounah, Nadia B., Orwitz, Nina, Woo, Janghee, Byrd, John C.

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: